Sprint Bioscience AB

Sprint Bioscience operates with a capital structure that is entirely equity-funded, as it has no long-term debt and a debt-to-equity ratio of 0.0. The company maintains a current ratio of 1.71, indicating that it has sufficient short-term assets to cover its short-term liabilities. However, the company reported negative operating and free cash flows of -9.29 million SEK and -3.57 million SEK, respectively, suggesting ongoing cash burn. The liquidity risk is assessed as low, but the company's reliance on equity financing could expose it to dilution risk if further capital is required. Profitability metrics for Sprint Bioscience are negative, with a return on equity (ROE) of -12.44% and a return on assets (ROA) of -5.87%. These figures are below the industry median for biotechnology firms, which typically exhibit positive ROE and ROA during growth phases. The company reported a gross profit of 10.78 million SEK but incurred an operating loss of 3.73 million SEK and a net loss of 3.07 million SEK. These results indicate that the company is not yet generating sufficient revenue to cover its operating costs. Geographically, Sprint Bioscience is primarily focused on the European market, with no disclosed revenue concentration in any specific region or segment. The company does not report revenue by business segment, which limits visibility into the performance of its various therapeutic areas or product candidates. The lack of segment reporting is common for early-stage biotechnology firms but may obscure strategic insights for investors. The company's growth trajectory is uncertain, as it has not provided forward-looking revenue guidance. Analysts have estimated a mean revenue of 81 million SEK for the current fiscal year, compared to the actual revenue of 167.17 million SEK in the prior year. This suggests a potential decline in revenue, which could be attributed to the company's focus on research and development rather than commercialization. The company's operating cash flow has also deteriorated, with a year-over-year decline from positive to negative. Risk factors for Sprint Bioscience include the high costs and uncertainties associated with drug development, regulatory approval risks, and the competitive landscape in the biotechnology sector. The company has not disclosed any immediate liquidity or dilution risks, but its negative cash flows and reliance on equity financing could expose it to dilution if additional capital is required. The dilution potential is currently assessed as low, but this could change if the company needs to raise further capital to fund its operations or clinical trials. Recent events for Sprint Bioscience include the advancement of its lead candidate, SP-1049, into Phase II clinical trials for psoriasis. The company has also expanded its research pipeline with preclinical programs in other inflammatory diseases. No recent filings or earnings transcripts have been disclosed that would indicate significant changes in the company's strategic direction or financial position.